Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 price target.
Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 price target.